Open-label evaluation of the skin-brightening efficacy of a skin-brightening system using decapeptide-12

This open-label clinical study, conducted by David J. Goldberg and colleagues at Skin Laser & Surgery Specialists in New York/New Jersey, was the first peer-reviewed work to evaluate the efficacy of decapeptide-12 (Lumixyl™) — a cosmetic peptide developed at Stanford — in diverse skin phototypes for the treatment of sun-induced facial hyperpigmentation. The context was the search for alternatives to hydroquinone, the gold standard but with relevant adverse effects (irritation, ochronosis, melanocyte cytotoxicity).

The study included 13 women with varied Fitzpatrick phototypes (I-VI) presenting moderate-to-severe solar hyperpigmentation. Participants used a cosmetic system containing 0.01% decapeptide-12 combined with supporting products (cleanser, moisturizer, sunscreen) for 24 weeks. Pigmentation was assessed by standardized photography, clinical scales, and tolerability questionnaires.

Results were clinically significant: 38.5% of patients achieved complete clearance of moderate photodamage lesions, 30.7% improved from moderate to mild, and additionally 30.8% improved from severe baseline pigmentation. Tolerability was excellent, with no irritation, erythema, peeling, or sensitization — an important advantage over hydroquinone, especially in higher phototypes where hydroquinone can cause paradoxical hyperpigmentation.

The proposed mechanism involves direct tyrosinase inhibition — the rate-limiting enzyme of melanin synthesis — by binding to specific sites on the enzyme or its mRNA, without melanocyte cytotoxicity. This work consolidated decapeptide-12 as a viable cosmeceutical ingredient for melasma, post-inflammatory hyperpigmentation, and photodamage treatment, paving the way for its incorporation into professional brightening formulations and dermocosmetics.